Levy Adam Scott 4

What Happened

• Adam Scott Levy, CFO and Secretary of Mineralys Therapeutics (MLYS), received equity awards on February 19, 2026. The filing shows a grant of 39,900 Restricted Stock Units (RSUs) and a derivative award covering 53,300 share-equivalents, both reported at $0.00 acquisition price. Combined, these awards represent 93,200 share-equivalents granted as compensation (no cash paid).

Key Details

• Transaction date: 2026-02-19; Form 4 filed 2026-02-20 (timely).
• Reported consideration: $0.00 (awarded as compensation).
• RSU grant: 39,900 RSUs (footnote F1) — each RSU converts to one share on vesting; vests in annual installments over four years (1/4 each year).
• Derivative grant: 53,300 share-equivalents (footnote F2 indicates an option-style award) — vests monthly over four years (1/48 each month).
• Shares owned after transaction: not specified in the provided Form 4 data.
• No sale, purchase, or cash exercise reported; these are compensation grants, not open-market trades.

Context

• RSUs become actual shares only as they vest; the derivative award appears to be an option-like instrument that vests monthly and does not represent immediately tradable shares until vested/exercised.
• Grants like these are common for executive compensation and do not by themselves indicate insider buying or selling intent.